A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

NCT07566052 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Setidegrasib
DRUG: Docetaxel

Sponsor

Astellas Pharma Global Development, Inc.